Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golocdacimab in diabetic peripheral arterial disease
NCT05912218Phase 2Active, not recruiting
- Sponsor
- National Heart Centre Singapore
- Start
- Nov 2023
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Peripheral Arterial Disease (PAD) comparing MEDI6570 with Placebo (2 arms). Primary endpoints: Lower limb atheroma plaque inflammation at 9 months and Lower limb microvascular perfusion at 9 months. Started Nov 2023; status: active, not recruiting.
02
Drugs
golocdacimab
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT05912218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05912218.